2[1]Cohn JN,Fowler MB,Bristow MR,et al.Safety and efficacy of carvedilol in severe heart failure[J].J Card Fail,1997,3:173.
3[2]Olsen SL,Gilbert ME,Renlund DG,et al.Carvedilol improves left ventricular function and symptoms in chronic heart failure:a double-blind randomized study[J].J Am Coll Cardiol,1995,25:1 225.
4[3]Packer M,Colucci WS,Sackner-Bernstein JD,et al.Double-blind,placebo-controlled study of the effects of carvedilol in patients with moderate to severe heart failure :the precise trial:prospective randomized evaluation of carvedilol on symptoms and exercise[J].Cir culation,1996,94:2 793.
5[4]Morgan T.Clinical pharmacokinetics and pharmacodynamics of carvedilol[J].Clin Pharmacokinet,1994,26:335.
6[5]Zhou HH,Wood AJ.Stereoselective disposition of carvedilol is determined by CYP2D6 [J].Clin Pharmacol Ther,1995,57:518.
7[6]Kraner BK,Ress KN,Erley CN,et al.Pharmacokinetic and blood pressure effects of carvedilol in patients with chronic renal failure[J].Eur J Clin Pharmacol,1992,43:85.
8[7]Ruffolo RR Jr,Sauernelch CF,Willette RN,et al.Hemodynamic differences between carvedilol and labetalol in the cutaneous circulation[J].Eur J Pharmacol,1990,38:(Suppl 2)S112.
9[8]Nichols AJ,Gellai M,Ruffolo RR Jr.Studies on the mechanism arterial vasodilation produced by the novel antihypertensive agent,carvediloi[J].Fundam Clin Pharmacol,1991,5:25.
10[9]Yue TL,Lysko PC,Barone FC,et al.Carvedilol,a new antihypertensive drug with unique antioxidant activity:potential role in cerebroprotection[J].NY Acad Sci,1994,738(1):230.
6Sun J,Yuan YZ,Holtmann G. Itopride in the treatment of functional dyspepsia in Chinese patients:a prospective,multicentre,post-marketingobservational study[J].Clin Drug Investig,2011,(12):865-875.
